115 related articles for article (PubMed ID: 22299770)
1. A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer.
Ishiguro M; Watanabe T; Yamaguchi K; Satoh T; Ito H; Seriu T; Sakata Y; Sugihara K
Jpn J Clin Oncol; 2012 Apr; 42(4):287-94. PubMed ID: 22327124
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and risk factors analysis of 505 cases of infusion reactions in a tertiary hospital.
Yin W; Wen B; Wang G; Wang Z; Kong X; Wu Y; Meng X; Ou X; Wei L; Yu P
Front Pharmacol; 2024; 15():1292347. PubMed ID: 38379900
[No Abstract] [Full Text] [Related]
3. Biomarkers for nonclinical infusion reactions in marketed biotherapeutics and considerations for study design.
Mease KM; Kimzey AL; Lansita JA
Curr Opin Toxicol; 2017 Jun; 4():1-15. PubMed ID: 29658009
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment.
Rombouts MD; Swart EL; VAN DEN Eertwegh AJM; Crul M
Anticancer Res; 2020 Mar; 40(3):1201-1218. PubMed ID: 32132017
[TBL] [Abstract][Full Text] [Related]
5. Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?
Dupont M; Carlier C; Gower-Rousseau C; Barbier-Lider P; Botsen D; Brasseur M; Burgevin A; Chourbagi C; D'Almeida R; Hautefeuille V; Hentzien M; Lambert A; Lamuraglia M; Lavau-Denes S; Lopez A; Parent D; Slimano F; Brugel M; Bouché O
BMC Cancer; 2022 Nov; 22(1):1219. PubMed ID: 36434607
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.
Fiedler W; Cresta S; Schulze-Bergkamen H; De Dosso S; Weidmann J; Tessari A; Baumeister H; Danielczyk A; Dietrich B; Goletz S; Zurlo A; Salzberg M; Sessa C; Gianni L
ESMO Open; 2018; 3(2):e000303. PubMed ID: 29464112
[TBL] [Abstract][Full Text] [Related]
7. First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.
Mross K; Richly H; Fischer R; Scharr D; Büchert M; Stern A; Gille H; Audoly LP; Scheulen ME
PLoS One; 2013; 8(12):e83232. PubMed ID: 24349470
[TBL] [Abstract][Full Text] [Related]
8. Role of Kampo medicine in integrative cancer therapy.
Yamakawa J; Motoo Y; Moriya J; Ogawa M; Uenishi H; Akazawa S; Sasagawa T; Nishio M; Kobayashi J
Evid Based Complement Alternat Med; 2013; 2013():570848. PubMed ID: 23997796
[TBL] [Abstract][Full Text] [Related]
9. Sustained zero-order release of intact ultra-stable drug-loaded liposomes from an implantable nanochannel delivery system.
Celia C; Ferrati S; Bansal S; van de Ven AL; Ruozi B; Zabre E; Hosali S; Paolino D; Sarpietro MG; Fine D; Fresta M; Ferrari M; Grattoni A
Adv Healthc Mater; 2014 Feb; 3(2):230-8. PubMed ID: 23881575
[TBL] [Abstract][Full Text] [Related]
10. Significance of Kampo, traditional Japanese medicine, in supportive care of cancer patients.
Yamakawa J; Motoo Y; Moriya J; Ogawa M; Uenishi H; Akazawa S; Sasagawa T; Nishio M; Kobayashi J
Evid Based Complement Alternat Med; 2013; 2013():746486. PubMed ID: 23861712
[TBL] [Abstract][Full Text] [Related]
11. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics.
Bylsma LC; Dean R; Lowe K; Sangaré L; Alexander DD; Fryzek JP
Cancer Med; 2019 Sep; 8(12):5800-5809. PubMed ID: 31376243
[TBL] [Abstract][Full Text] [Related]
12. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
14. The safety of monoclonal antibodies for treatment of colorectal cancer.
Berger MD; Lenz HJ
Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510
[TBL] [Abstract][Full Text] [Related]
15. Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer.
Song X; Long SR; Barber B; Kassed CA; Healey M; Jones C; Zhao Z
Curr Clin Pharmacol; 2012 Feb; 7(1):56-65. PubMed ID: 22299770
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab.
Foley KA; Wang PF; Barber BL; Long SR; Bagalman JE; Wagner V; Song X; Zhao Z
Ann Oncol; 2010 Jul; 21(7):1455-1461. PubMed ID: 20100773
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
